Pooja Goswami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pooja Goswami has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Biplob Koch
Genotoxicology and Cancer Biology Laboratory, Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi, India
5 shared publications - Abhishek Jha
Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi, India
4 shared publications - Brahmeshwar Mishra
Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi, India
4 shared publications - Manish Kumar
Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi, India
4 shared publications - Manjit Manjit
Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi, India
4 shared publications - Kanchan Bharti
Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi, India
3 shared publications
Latest Publications
- Open Access
- 12 February 2025
- Published by Springer Nature in Discover Nano
- Vol. 20 (1) , 1-19
Fabrication of lipid-modified drug nanocrystals loaded injectable hydrogel for breast cancer therapy
The current study includes the design of soluplus stabilized, lipid-coated, and fucoidan-oleylamine conjugate modified paclitaxel nanocrystals. The nanocry
- 12 February 2025
- Published by Springer Nature in Discover Nano
- Vol. 20 (1) , 1-19
Open AccessFabrication of lipid-modified drug nanocrystals loaded injectable hydrogel for breast cancer therapy
The current study includes the design of soluplus stabilized, lipid-coated, and fucoidan-oleylamine conjugate modified paclitaxel nanocrystals. The nanocry
- Open Access
- 24 November 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-18
Formulation and evaluation of cetuximab functionalized phospholipid modified nanocrystals of paclitaxel for non-small cell lung cancer therapy
Present work aims to prepare Soluplus stabilized, phospholipid-modified, and cetuximab-conjugated paclitaxel nanocrystals (NCs) as stable nanocarriers for targeted drug delivery. The NCs, prepared using concurrent antisolvent precipitation cum cold crystallization method followed by probe sonication, were found to be monodispersed particles with sub-200 nm size. The microscopic analysis uncovered rod and spherical anisotropy for Soluplus stabilized (PTX-NCs) and phospholipid modified (Lipid/PTX-NCs) nanocrystals, respectively. The formation of amorphous PTX-NCs and subsequent coating with phospholipid was confirmed by solid-state characterization using differential scanning calorimetry (DSC), X-ray diffraction (XRD), and Fourier transform Infrared Spectroscopy (FTIR). X-ray Photoelectron Spectroscopic (XPS) analysis, indicated successful conjugation of cetuximab on NCs surface. Lipid coating rendered a sustained drug release behaviour to NCs at physiological pH. In vitro cell line studies confirmed the improved cellular internalization and better apoptosis induction capability of NCs, consequently resulting in enhanced efficacy of PTX against A549 cancer cells. Moreover, in Benzo[a] pyrene-induced lung cancer model, Cmab/Lipid/PTX-NCs showed significant improvement in tumor inhibition potential in comparison to pure PTX. The prepared Cmab/Lipid/PTX-NCs also exhibited improved pharmacokinetics performance, avoided off-target distribution, and showed a reduction in systemic toxicity. The findings of this study indicate the promising potential of the prepared cetuximab-functionalized phospholipid-coated paclitaxel nanocrystals in lung cancer therapy.
- 24 November 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-18
Open AccessFormulation and evaluation of cetuximab functionalized phospholipid modified nanocrystals of paclitaxel for non-small cell lung cancer therapy
Present work aims to prepare Soluplus stabilized, phospholipid-modified, and cetuximab-conjugated paclitaxel nanocrystals (NCs) as stable nanocarriers for targeted drug delivery. The NCs, prepared using concurrent antisolvent precipitation cum cold crystallization method followed by probe sonication, were found to be monodispersed particles with sub-200 nm size. The microscopic analysis uncovered rod and spherical anisotropy for Soluplus stabilized (PTX-NCs) and phospholipid modified (Lipid/PTX-NCs) nanocrystals, respectively. The formation of amorphous PTX-NCs and subsequent coating with phospholipid was confirmed by solid-state characterization using differential scanning calorimetry (DSC), X-ray diffraction (XRD), and Fourier transform Infrared Spectroscopy (FTIR). X-ray Photoelectron Spectroscopic (XPS) analysis, indicated successful conjugation of cetuximab on NCs surface. Lipid coating rendered a sustained drug release behaviour to NCs at physiological pH. In vitro cell line studies confirmed the improved cellular internalization and better apoptosis induction capability of NCs, consequently resulting in enhanced efficacy of PTX against A549 cancer cells. Moreover, in Benzo[a] pyrene-induced lung cancer model, Cmab/Lipid/PTX-NCs showed significant improvement in tumor inhibition potential in comparison to pure PTX. The prepared Cmab/Lipid/PTX-NCs also exhibited improved pharmacokinetics performance, avoided off-target distribution, and showed a reduction in systemic toxicity. The findings of this study indicate the promising potential of the prepared cetuximab-functionalized phospholipid-coated paclitaxel nanocrystals in lung cancer therapy.
- Open Access
- 13 September 2024
- Published by Royal Society of Chemistry (RSC) in Materials Advances
- Vol. 5 (19) , 7789-7808
Cabazitaxel-loaded redox-responsive nanocarrier based on d-alpha-tocopheryl-chitosan and hyaluronic acid for improved anti-tumor efficacy in DMBA-induced breast cancer model
The study involved the formulation of cabazitaxel loaded D-alpha-tocopheryl succinate/chitosan conjugate (CSVE) and hyaluronic acid (HA) based redox-responsive nanoparticles crosslinked using 3,3′-dithiodipropionic acid (DTPA). The nanoparticle surface was functionalized with cetuximab (Cmab) to give CSVE/HA/DTPA/Cmab NP for EGFR targeted delivery of the payload. The formulations were subjected to particle analysis, morphological assessment, solid-state characterization, and in vitro drug release studies. The results showed cationic, sub-200 nm sized spherical particles with the glutathione-responsive release of cabazitaxel. In vitro studies revealed a marked decrease in the IC50 value, improved cellular uptake, and a superior apoptotic effect. To determine the in vivo efficacy of the formulation, pharmacokinetic assessment, tumor regression analysis, and survival analysis were performed. The nanoparticles showed improved pharmacokinetic and anti-tumor efficacy compared to free cabazitaxel. The prepared nanoparticles demonstrated immense potential in targeted delivery of the payload for enhanced breast cancer therapy.
- 13 September 2024
- Published by Royal Society of Chemistry (RSC) in Materials Advances
- Vol. 5 (19) , 7789-7808
Open AccessCabazitaxel-loaded redox-responsive nanocarrier based on d-alpha-tocopheryl-chitosan and hyaluronic acid for improved anti-tumor efficacy in DMBA-induced breast cancer model
The study involved the formulation of cabazitaxel loaded D-alpha-tocopheryl succinate/chitosan conjugate (CSVE) and hyaluronic acid (HA) based redox-responsive nanoparticles crosslinked using 3,3′-dithiodipropionic acid (DTPA). The nanoparticle surface was functionalized with cetuximab (Cmab) to give CSVE/HA/DTPA/Cmab NP for EGFR targeted delivery of the payload. The formulations were subjected to particle analysis, morphological assessment, solid-state characterization, and in vitro drug release studies. The results showed cationic, sub-200 nm sized spherical particles with the glutathione-responsive release of cabazitaxel. In vitro studies revealed a marked decrease in the IC50 value, improved cellular uptake, and a superior apoptotic effect. To determine the in vivo efficacy of the formulation, pharmacokinetic assessment, tumor regression analysis, and survival analysis were performed. The nanoparticles showed improved pharmacokinetic and anti-tumor efficacy compared to free cabazitaxel. The prepared nanoparticles demonstrated immense potential in targeted delivery of the payload for enhanced breast cancer therapy.
- 25 January 2024
- Published by Springer Nature in Silicon
- Vol. 16 (6) , 2577-2591
Study of Human Osteosarcoma Cell Line Growth, Hemocompatibility, In-vitro Analysis and Physical Properties of V2O5 Substituted Borosilicate Glass
- 25 January 2024
- Published by Springer Nature in Silicon
- Vol. 16 (6) , 2577-2591
Study of Human Osteosarcoma Cell Line Growth, Hemocompatibility, In-vitro Analysis and Physical Properties of V2O5 Substituted Borosilicate Glass